Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
NEW YORK, Feb. 16, 2022 /PRNewswire/ — Cambrian Biopharma, a multi-asset longevity biotech, today announced a licensing agreement with Novartis to advance novel, selective compounds designed and characterized by Novartis to target the mechanistic target of rapamycin (mTOR) pathway. The…
Comments Off on Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors